News IceCure Medical Ltd

Equities

ICCM

IL0011224156

Market Closed - Nasdaq Other stock markets 04:30:01 2024-07-08 pm EDT			5-day change	1st Jan Change
0.748 ^USD	+2.47%		+1.77%	-30.09%

Jul. 01	U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes	CI
Jun. 04	FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes	Jul. 01	PR
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense Cryoablation System with CryoProbes	Jul. 01	CI
IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024	Jun. 18	PR
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference, Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function	Jun. 13	AQ
Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function	Jun. 12	PR
FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan	Jun. 04	PR
FDA to Convene Advisory Panel for Review of IceCure Medical Ltd.'s De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025	Jun. 04	CI
IceCure Medical : Company Presentation	Jun. 03	PU
IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024	May. 29	AQ
Transcript : IceCure Medical Ltd, Q1 2024 Earnings Call, May 28, 2024	May. 28
Earnings Flash (ICCM) ICECURE MEDICAL Posts Q1 Revenue $743,000, vs. Street Est of $880,000	May. 28	MT
IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024	May. 21	PR
IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase	May. 20	PR
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally	May. 07	PR
Icecure Medical Ltd. Announces That Positive Data from an Independent Study (The "Study") Performed in Japan Was Published in an Article Titled "Percutaneous Ultrasound?Guided Cryoablation for Early?Stage Primary Breast Cancer: A Follow?Up Study in Japan," in the Journal Breast Cancer on April 27, 2024	May. 07	CI
IceCure Medical : Company Presentation	Apr. 23	PU
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate, Data Submitted to FDA Requesting Marketing Authorization	Apr. 16	AQ
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	Apr. 15	MT
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense	Apr. 15	CI
IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes	Apr. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News IceCure Medical Ltd

Equities

ICCM

IL0011224156

Summary

Filters